Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Comparisons of clinical outcomes in women with advanced ovarian cancer treated with frontline intraperitoneal versus dose-dense platinum/paclitaxel chemotherapy without bevacizumab
 
  • Details

Comparisons of clinical outcomes in women with advanced ovarian cancer treated with frontline intraperitoneal versus dose-dense platinum/paclitaxel chemotherapy without bevacizumab

Journal
International Journal of Environmental Research and Public Health
Journal Volume
17
Journal Issue
10
Pages
3603
Date Issued
2020
Author(s)
Ting W.-H.
Hsiao C.-H.
Chen H.-H.
Wei M.-C.
HO-HSIUNG LIN  
Hsiao S.-M.
DOI
10.3390/ijerph17103603
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085266205&doi=10.3390%2fijerph17103603&partnerID=40&md5=6087f641bc9e085ba7e33a9a51673330
https://scholars.lib.ntu.edu.tw/handle/123456789/550149
Abstract
Background: We aimed to compare the clinical outcomes between intraperitoneal chemotherapy and dose-dense chemotherapy for the frontline treatment of advanced ovarian, fallopian tube and primary peritoneal cancer in women not receiving bevacizumab. Methods: All consecutive women with stage II~IV cancer treated with either frontline intraperitoneal or dose-dense platinum/paclitaxel chemotherapy and not receiving bevacizumab between March 2006 and June 2019 were reviewed. Results: A total of 50 women (intraperitoneal group, n = 22; dose-dense group, n = 28) were reviewed. Median progression-free survival (32.6 months versus 14.2 months; adjusted hazard ratio = 0.38; 95% CI = 0.16 to 0.90, p = 0.03) and overall survival (not reached versus 30.7 months; adjusted hazard ratio = 0.23, 95% CI = 0.07 to 0.79, p = 0.02) were significantly higher in the intraperitoneal group than in the dose-dense group. A multivariable Cox proportional-hazards model also indicated that the number of frontline chemotherapy cycles (adjusted hazard ratio = 0.66, 95% CI 0.47 to 0.94, p = 0.02) was a predictor of better overall survival. Nausea/vomiting and nephrotoxicity occurred more frequently in the intraperitoneal group (p = 0.02 and <0.0001, respectively). Conclusions: Intraperitoneal chemotherapy seems to be superior in progression free survival and overall survival to dose-dense chemotherapy in the frontline treatment of women with optimally resected advanced ovarian, fallopian tube or primary peritoneal cancer and not receiving bevacizumab. ? 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Subjects
Adjuvant; Chemotherapy; Cytoreduction; Ovarian neoplasms; Peritoneum
SDGs

[SDGs]SDG3

Other Subjects
bevacizumab; carboplatin; cisplatin; paclitaxel; antineoplastic agent; bevacizumab; carboplatin; paclitaxel; platinum; cancer; chemotherapy; comparative study; drug; multivariate analysis; survival; womens health; adult; advanced cancer; anemia; Article; cancer chemotherapy; cancer staging; cancer survival; clinical article; clinical outcome; comparative study; controlled study; diagnostic test accuracy study; diarrhea; dose densification; drug dosage form comparison; female; human; leukopenia; liver toxicity; middle aged; multiple cycle treatment; nausea; nephrotoxicity; neurotoxicity; ovary cancer; overall survival; peritoneum cancer; predictor variable; progression free survival; receiver operating characteristic; sensitivity and specificity; survival prediction; thrombocytopenia; uterine tube carcinoma; vomiting; young adult; disease free survival; ovary tumor; parenteral drug administration; uterine tube tumor; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum
Publisher
MDPI AG
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science